In a patient on insulin with IA-2 (islet antigen‑2) autoantibody <5.4, zinc transporter 8 (ZnT8) autoantibody <10, and insulin autoantibody <0.4, what does this autoantibody profile indicate and how should management be approached?

Negative Autoantibody Profile in an Insulin-Treated Patient: Likely Type 2 Diabetes or Antibody-Negative Type 1 Diabetes

This patient has negative islet autoantibodies (IA-2 <5.4, ZnT8 <10, insulin autoantibody <0.4) while on insulin therapy, indicating either type 2 diabetes requiring insulin or the 5-10% of type 1 diabetes cases that are antibody-negative.

Interpretation of the Autoantibody Profile

Your patient's autoantibody results are all negative:

• IA-2 autoantibody: <5.4 (negative)
• ZnT8 autoantibody: <10 (negative)
• Insulin autoantibody: <0.4 (negative)
• GAD antibody: Not reported (should be measured)

According to the 2025 ADA Standards of Care, GAD should be the primary antibody measured first, followed by IA-2 and ZnT8 if GAD is negative 1. The insulin autoantibody is only useful in individuals who have not been treated with insulin, as exogenous insulin can induce antibody formation 1, 2. Since your patient is already on insulin, the insulin autoantibody result is not interpretable for diagnostic purposes.

Critical Next Step: Measure GAD Antibody

You must measure GAD antibody (GADA) before making any classification decision. GAD is by far the most common autoantibody in adult-onset autoimmune diabetes, particularly in LADA 3. The current testing is incomplete without it 1, 2.

Classification Algorithm Based on Age and Clinical Features

If Patient is <35 Years Old:

• Even with negative antibodies, type 1 diabetes remains the working diagnosis 1, 2
• 5-10% of adult-onset type 1 diabetes patients are antibody-negative 1, 2
• Continue insulin therapy
• Measure C-peptide to assess residual beta-cell function (see below)

If Patient is ≥35 Years Old:

The classification depends on clinical features and C-peptide testing 1:

Assess for Type 2 Diabetes Features:

• BMI ≥25 kg/m²
• Absence of weight loss
• Absence of ketoacidosis at presentation
• Less marked hyperglycemia at diagnosis
• Features of metabolic syndrome
• Longer duration and milder symptoms before presentation 1

If Type 2 Features Present:

• Consider trial of non-insulin therapy if C-peptide >600 pmol/L (>1.8 ng/mL) 1
• This suggests sufficient beta-cell reserve for non-insulin agents

If Type 2 Features Absent:

• Likely antibody-negative type 1 diabetes
• Continue insulin therapy
• Monitor for progression

C-Peptide Testing Protocol

C-peptide measurement is essential for classification in insulin-treated patients 1:

Timing and Method:

• Random sample within 5 hours of eating with concurrent glucose
• Do NOT test within 2 weeks of hyperglycemic emergency
• Do NOT discontinue insulin before testing 1

Interpretation:

• >600 pmol/L (>1.8 ng/mL): Suggests type 2 diabetes; trial of non-insulin therapy may be appropriate 1
• 200-600 pmol/L: Indeterminate; clinical judgment required
• <200 pmol/L: Suggests type 1 diabetes; continue insulin 1
• <80 pmol/L (<0.24 ng/mL): Severe insulin deficiency; no need to repeat 1

Important Caveats:

• If result is <600 pmol/L and concurrent glucose is <70 mg/dL or patient may have been fasting, consider repeating
• If result is >600 pmol/L, circumstances of testing don't matter 1

Consider Monogenic Diabetes

Screen for monogenic diabetes features 1:

• HbA1c <7.5% at diagnosis
• One parent with diabetes
• Specific features: renal cysts, partial lipodystrophy, maternally inherited deafness
• Severe insulin resistance without obesity
• Monogenic diabetes calculator probability >5% (diabetesgenes.org)

If features present and C-peptide >200 pmol/L, genetic testing should be pursued 1.

Management Approach

Continue Insulin Therapy While Evaluating:

• Maintain current insulin regimen to prevent hyperglycemia and DKA 4
• Monitor blood glucose frequently 4
• Periodic HbA1c measurement 4

After Complete Evaluation:

1. If antibody-negative type 1 diabetes confirmed: Continue insulin indefinitely
2. If type 2 diabetes confirmed with adequate C-peptide: Consider gradual transition to non-insulin agents under close monitoring
3. If monogenic diabetes confirmed: Adjust therapy based on specific genetic diagnosis

Common Pitfalls to Avoid

• Do not stop insulin before completing evaluation - risk of DKA in unrecognized type 1 diabetes 4
• Do not interpret insulin autoantibody in insulin-treated patients - exogenous insulin induces antibodies 1, 2
• Do not skip GAD antibody testing - it's the most sensitive marker in adults 1, 3
• Do not test C-peptide during acute illness or within 2 weeks of DKA - results will be falsely low 1
• Do not assume antibody-negative means not type 1 diabetes in young patients - 5-10% are antibody-negative 1, 2